{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83d\udc8a Block. Beat. Benefit. The Hidden Strength of \u03b2-Blockers Post-MI","description":"\ud83d\udea8 New Meta-Analysis Alert! \ud83d\udc8a\ud83e\udec0 Can \u03b2-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40\u201349%)? &amp;nbsp; \ud83d\udcca An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with \u03b2-blockers vs. control (HR 0.75; p=0.031) \u2014 even in the absence of clinical heart failure. &amp;nbsp; \ud83c\udf0d Consistent across trials and countries. Most benefit seen in patients &amp;lt;75 years. \ud83d\udcda This could shift guidelines for a large overlooked population. &amp;nbsp; \ud83d\udd17 Read more in The Lancet (Aug 30, 2025) #Cardiology #BetaBlockers #MyocardialInfarction #LVEF #EvidenceBasedMedicine #MetaAnalysis #HeartHealth \ud83d\udc93\ud83d\udcc9 ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/38042240\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/192525125"}